Regulatory bodies and research institutions should monitor and publicly report on the gender composition of clinical trial participants. Transparent reporting can highlight areas of improvement, hold researchers accountable, and push the scientific community toward more equitable practices.
- Log in or register to contribute
Contribute to three or more articles across any domain to qualify for the Contributor badge. Please check back tomorrow for updates on your progress.